Dupont Capital Management Corp decreased its holdings in PerkinElmer, Inc. (NYSE:PKI) by 75.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,300 shares of the medical research company’s stock after selling 3,958 shares during the quarter. Dupont Capital Management Corp’s holdings in PerkinElmer were worth $125,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc raised its holdings in PerkinElmer by 1.7% in the third quarter. Vanguard Group Inc now owns 11,628,380 shares of the medical research company’s stock valued at $1,131,092,000 after acquiring an additional 198,673 shares in the last quarter. BlackRock Inc. raised its holdings in PerkinElmer by 7.4% in the fourth quarter. BlackRock Inc. now owns 7,001,732 shares of the medical research company’s stock valued at $549,985,000 after acquiring an additional 482,906 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in PerkinElmer by 10.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,766,757 shares of the medical research company’s stock valued at $295,879,000 after acquiring an additional 353,534 shares in the last quarter. Geode Capital Management LLC raised its holdings in PerkinElmer by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 1,522,499 shares of the medical research company’s stock valued at $119,450,000 after acquiring an additional 124,168 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in PerkinElmer by 0.9% in the fourth quarter. Northern Trust Corp now owns 1,068,924 shares of the medical research company’s stock valued at $83,965,000 after acquiring an additional 9,454 shares in the last quarter. 96.25% of the stock is owned by institutional investors and hedge funds.
PKI stock opened at $87.91 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.17 and a current ratio of 1.68. PerkinElmer, Inc. has a twelve month low of $71.31 and a twelve month high of $103.00. The company has a market cap of $9.77 billion, a price-to-earnings ratio of 24.35, a P/E/G ratio of 1.56 and a beta of 1.22.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. PerkinElmer had a net margin of 8.89% and a return on equity of 15.98%. The company had revenue of $648.70 million for the quarter, compared to analysts’ expectations of $645.38 million. During the same quarter last year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was up .7% on a year-over-year basis. As a group, analysts predict that PerkinElmer, Inc. will post 4.05 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.32%. PerkinElmer’s payout ratio is currently 7.76%.
In other PerkinElmer news, insider Daniel R. Tereau sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $93.27, for a total transaction of $111,924.00. Following the sale, the insider now owns 5,839 shares of the company’s stock, valued at $544,603.53. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 24,465 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $92.81, for a total transaction of $2,270,596.65. Following the sale, the insider now directly owns 84,277 shares in the company, valued at approximately $7,821,748.37. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,274 shares of company stock worth $5,238,106. 1.80% of the stock is owned by corporate insiders.
Several brokerages recently weighed in on PKI. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Wednesday, April 3rd. Goldman Sachs Group raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Tuesday, April 9th. Piper Jaffray Companies raised their target price on shares of PerkinElmer to $104.00 and gave the company an “overweight” rating in a report on Friday, February 1st. Royal Bank of Canada reaffirmed a “hold” rating and issued a $41.00 target price on shares of PerkinElmer in a report on Friday, May 3rd. Finally, Desjardins reaffirmed an “average” rating and issued a $45.00 target price on shares of PerkinElmer in a report on Wednesday, January 16th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. PerkinElmer has a consensus rating of “Hold” and a consensus target price of $82.32.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://macondaily.com/2019/05/16/dupont-capital-management-corp-sells-3958-shares-of-perkinelmer-inc-pki.html.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Recommended Story: How to Invest in an Index Fund
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.